Liminatus Pharma, Inc.
Liminatus Pharma, Inc.
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|
Related Party | - | 0 | 0 | 0 | -2 | 2 | |||||
Assets | |||||||||||
Accrued Liabilities Current | - | - | - | - | - | 0 | |||||
Assets Current | |||||||||||
Cash | 3 | 2 | 0 | 1 | 1 | - | |||||
Deferred Costs Current | - | - | 0 | - | - | - | |||||
Prepaid Expense And Other Assets Current | 0 | 1 | 0 | 0 | 0 | - | |||||
Assets Current | 3 | 3 | 1 | 1 | 2 | - | |||||
Assets Noncurrent | |||||||||||
Receivable From Shareholders Or Affiliates For Iss… | - | - | - | - | - | -0 | |||||
Other Receivable After Allowance For Credit Loss N… | - | - | - | 0 | 0 | - | |||||
Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | - | |||||
Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | - | |||||
Assets | 3 | 3 | 1 | 1 | 2 | - | |||||
Liabilities And Stockhold… | |||||||||||
Liabilities Current | |||||||||||
Accounts Payable And Accrued Liabilities Current | 1 | 1 | 1 | 1 | 0 | - | |||||
Short Term Borrowings | 1 | 1 | 1 | 1 | 1 | - | |||||
Liabilities Current | 3 | 3 | 10 | 3 | 11 | - | |||||
Warrants And Rights Outstanding | 0 | 0 | 0 | 0 | 0 | - | |||||
Liabilities | 3 | 3 | 10 | 3 | 11 | 0 | |||||
Stockholders Equity | |||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 42 | 40 | 29 | 29 | 20 | 0 | |||||
Retained Earnings Accumulated Deficit | -41 | -40 | -39 | -31 | -29 | -0 | |||||
Stockholders Equity | 0 | -0 | -10 | -2 | -9 | -20 | |||||
Liabilities And Stockholders Equity | 3 | 3 | 1 | 1 | 2 | - | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | - | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | - | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | |||||
Common Stock Shares Issued | 56 | 45 | 27 | 27 | 26 | 0 | |||||
Shares Outstanding | 56 | 45 | - | - | - | - | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -21.11% | -20.56% | -42.78% | - | - | - | - | - | - | - | - | - |
| 2025 | 75.88% | 61.60% | -36.73% | -19.65% | -39.88% | -62.60% | -21.59% | -40.09% | -48.60% | 15.12% | -1.74% | -30.81% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Liminatus Pharma, Inc. (LIMN) — SEC Financial Statements & Analysis
Liminatus Pharma, Inc. (LIMN) is a biological products, (no diagnostic substances) company, incorporated in DE. Liminatus Pharma, Inc. trades on Nasdaq as: LIMN, LIMNW. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Liminatus Pharma, Inc. reported a Debt-to-Equity ratio of 10.32x, a Price-to-Book (P/B) ratio of 885.50x (TTM), at a market cap of $266.19M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 10.32x
- P/B TTM
- 885.50x
- Market Cap
- $266.19M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Liminatus Pharma, Inc. in?
Liminatus Pharma, Inc. (LIMN) operates in the Biological Products, (No Diagnostic Substances) industry.
What is LIMN's market cap?
Liminatus Pharma, Inc. (LIMN) has a market capitalization of $266.19M as of 2026-06-30.
What exchange does LIMN trade on?
Liminatus Pharma, Inc. (LIMN) trades on the Nasdaq.
Where is Liminatus Pharma, Inc. incorporated?
Liminatus Pharma, Inc. is incorporated in DE.